[Skip to Content]
[Skip to Content Landing]
Practice Gaps
June 20, 2011

Include Discussions and Review of Systems Regarding Inflammatory Bowel Disease in Patients Starting Isotretinoin TherapyComment on “Isotretinoin Therapy and Inflammatory Bowel Disease”

Author Affiliations

Author Affiliation: Division of Internal Medicine, Dermatology Section and Dermatology, Northeastern Ohio Universities Colleges of Medicine and Pharmacy, Case Western Reserve College of Medicine, Akron.

Arch Dermatol. 2011;147(6):729-730. doi:10.1001/archdermatol.2011.131

The use of isotretinoin therapy in dermatology has become complicated by regulatory and medicolegal issues. Still, isotretinoin for severe acne has been a mainstay of dermatologic therapy since its Food and Drug Adminstration approval in 1982. While dermatologists have become adept at addressing the drug's well-known teratogenic adverse effects and potential associations with depression and suicidal ideation, a knowledge gap may exist for many dermatologists to address clinical care questions related to isotretinoin therapy and IBD. The article by Popescu and Popescu1 in this issue of Archives helps to narrow this gap and potential knowledge gaps related to general epidemiologic principles about causation.

First Page Preview View Large
First page PDF preview
First page PDF preview
×